Overcome the challenges of PMS2 variant calling with Devyser LynchFAP – our new NGS solution
Devyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
Oncology
Precise. Personalized. Preventive.
Genetic diagnostic testing for cancer is centerstage as oncology transitions to precision medicine and personalized treatment. Our fast, accurate DNA tests assist in detection and prevention – and help drive the development of individualized therapies. At a time when genetic oncology grows at unprecedented speed, we believe that, in some cases, less is more.
Less disease, longer lives
Cancer treatment is changing fast. The shift to precision medicine and personalized therapies is rapid and real. Genetic testing is a crucial enabler of this transformation..
At a time when genetic oncology is growing at unprecedented speed, we believe that less is sometimes more.
Increased preventive DNA cancer screening makes it possible to identify more individuals at risk. It can also help combat the rising incidence of some cancer types in an aging population.
Our diagnostic tests for breast, ovarian and other cancers identify clinically significant variants with unsurpassed accuracy. Their high user convenience and fast, actionable results support the drive towards individualized cancer diagnostics.
A single-tube format generates a simple workflow with short hands-on time. User-friendly analysis software ensures effective automation throughout the process.
The end-to-end procedure is fully CE IVD-certified in compliance with the EU’s In-Vitro Diagnostic Medical Device Directive, guaranteeing robust results in clinical use that you can trust.
One tube per patient sample - no sample splitting
45
Less than 45 minutes hands-on time
CE-IVD
CE-IVD certified solution – from sample to result
Breast cancer
Breast cancer is the leading cause of cancer-related death in women. An estimated one in eight will develop the disease in their lifetime, while ovarian cancer is responsible for more deaths than any other cancer of the female reproductive system. We provide diagnostic solutions to cover women along the whole way – from prevention to treatment. Our germline mutation analysis identifies those who are at risk of developing breast and ovarian cancer and detects individuals who may benefit from risk-reducing strategies. Our somatic mutation analysis identifies women who may benefit from targeted treatment using PARP inhibitor.
News | April 16, 2024
Devyser receives MDSAP certification for BrazilNews | Feb 20, 2024
Devyser Diagnostics AB publishes year-end report for January to December 2023News | Feb 06, 2024
Devyser strengthens its management team
Devyser launches two new genetic testing solutions for hereditary cancer
Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA...
Simplify your lab workflow with single-tube NGS library preparation method
As a lab manager, you know the importance of streamlining workflows to maximize productivity and...
NGS identification of both male and female cancer risks
Do you know a man who has participated at least once in “Movember”? Every year, thousands of men...
Featured products
What are the latest trends in genetic screening for breast and ovarian cancer, and what does the scientific research mean for you and your laboratory? 